Life after the CF franchise

Every headline she wants is about a drug that isn't for cystic fibrosis

Guidance, an acquisition and a pending approval are all arguments that Vertex is more than its CF book.

cf still pays for everything, and that's exactly the problem. the whole point of a $10b deal and a kidney filing is to make the next investor question be about something other than trikafta's patent cliff.

Diversification framing anchors earnings coverage